兒童風濕疾病及其醫療利用與罹癌風險之探討

A population-based cohort study of the risk of cancer in children with rheumatic disease and their precancerous medical utilization

10.6288/TJPH201736106027

馬震中(CHEN-CHUNG MA)；蘇有村(YU-TSUN SU)；林佟威(TUNG-WEI LIN)；鄭怡婷(I-TING CHENG)

兒童 ； 風濕疾病 ； 癌症 ； 醫療利用 ； children ； pediatric rheumatic disease ； cancer ； medical utilization

台灣公共衛生雜誌

36卷4期（2017 / 08 / 15）

386 - 396

繁體中文

目標：風濕疾病為一種慢性的炎症，可能會增加罹癌風險，因此本研究目的在探討台灣地區兒童風濕病人罹癌之風險及其罹癌前醫療利用之情形。方法：本研究採回溯性研究設計，運用次級資料分析，資料來源為全民健保資料庫，選取2000年至2012年診斷為風濕疾病之兒童，以紅斑性狼瘡及幼年特發性關節炎等八種風濕疾病進行觀察；使用Cox models分析罹癌症風險，並以Mann-Whitney U Test檢定病人罹癌前醫療利用之變化。結果：整體兒童風濕病人相較於兒童非風濕病人高出3.71倍罹癌風險，其中紅斑性狼瘡、幼年特發性關節炎與修格連氏症候群的罹癌風險分別為3.94倍、5.93倍與5.29倍；藥物中，曾使用免疫調節劑者罹癌風險約增加5.65倍，曾使用生物製劑罹癌風險高出約26.01倍；另外，兒童風濕病人在罹癌前的醫療利用變化呈現門診利用增加、住院利用減少，經Mann-Whitney U Test檢定均未達顯著差異。結論：綜合研究結果，兒童罹患風濕疾病會增加其罹癌風險，因此本研究建議衛生主管機關應加強重視兒童風濕病人的醫療照護，避免將來支出更多的社會成本。

Objectives: A clinical manifestation of rheumatic disease is chronic inflammation that may increase the risk of cancer. The purpose of this study was to explore the risk of cancer and the precancerous medical utilization by children with rheumatism in Taiwan. Methods: This was a retrospective study with secondary data analysis. The data were drawn from the National Health Insurance Research Database from 2000 to 2012. Patients under the age of 18 with a diagnosis of pediatric rheumatic disease, including systemic lupus erythematosus, juvenile idiopathic arthritis, Sjögren’s syndrome, scleroderma, polymyositis, dermatomyositis, vasculitis and Behçet’s disease. A total of 1,741 cases were identified. The Cox proportional hazards model was used to analyze the risk of cancer, and the Mann-Whitney U Test was used to assess whether the patient’s medical use was different from that in the year prior to the diagnosis of cancer. Results: The overall risk for children with rheumatism compared with non-rheumatic patients was 3.71 times the risk for cancer; for systemic lupus erythematosus, juvenile idiopathic arthritis and Sjögren's syndrome, the cancer risk was 3.94 times, 5.93 times and 5.29 times, respectively. The risk for cancer was increased by 5.65 times in those who had used immunoregulatory drugs, and this was 26.01 times more than that of those who had used biological agents. For children with rheumatism, in the year before the diagnosis of cancer and in terms of overall medical use before cancer, the number of outpatient visits and expenses increased, but the number of hospitalizations, hospital days, and cost reduction were not significantly different. Conclusions: Based on the results of this study, we suggest that the health authorities pay more attention to the medical care of children with rheumatism in order to avoid future social costs.

1. 蔡維河、侯素秋、黎家銘、楊清泉(2011)。台灣阿茲海默症病人確診前的門診醫療利用。台灣衛誌，30，316-25。
   連結：
2. 鄧正梁：病從何入？從「免疫」談起⋯獨一無二的紅斑性狼瘡！http://blog.xuite.net/liang310/LE/8330878。引用2015/12/23。Deng ZL. How do illnesses find their way in? A discussion of lupus erythematosus from the perspective of immunity! Available at: http://blog.xuite.net/liang310/LE/8330878. Accessed December 23, 2015. [In Chinese]
3. 台灣兒科醫學會： 轉知「行政院衛生署」來函。http://www.pediatr.org.tw/news/news_info.asp?id=129。引用2015/12/23。Taiwan Pediatric Association. A letter forwarded to the Department of Health, Executive Yuan. Available at: http://www.pediatr.org.tw/news/news_info.asp?id=129. Accessed December 23, 2015. [In Chinese]
4. 財團法人風濕病基金會：淋巴球與免疫病。http://www.arthritisfound.org.tw/doctor-acticle/%E6%B7%8B%E5%B7%B4%E7%90%83%E8%88%87%E5%85%8D%E7%96%AB%E7%97%85/。引用2015/12/23。Arthritis Foundation. Lymphatic and immune diseases. Available at: http://www.arthritisfound.org.tw/doctor-acticle/%E6%B7%8B%E5%B7%B4%E7%90%83%E8%88%87%E5%85%8D%E7%96%AB%E7%97%85/. Accessed December 23, 2015. [In Chinese]
5. 衛生福利部中央健保署：治療「類風濕性關節炎」生物製劑之健保給付現況。http://www.nhi.gov.tw/information/NewsDetail.aspx?No=1003&menu=9&menu_id=544。引用2016/05/30。National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). The status of National Health Insurance payments for biological agents to treat rheumatoid arthritis. Available at: http://www.nhi.gov.tw/information/NewsDetail.aspx?No=1003&menu=9&menu _id=544. Accessed May 30, 2016. [In Chinese]
6. 衛生福利部中央健保署：健保用藥品項查詢。http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata_id=3510&WD_ID=851。引用2016/02/15。National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). An inquiry into National Health Insurance medication use. Available at: http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata_id=3510&WD_ID=851. Accessed February 15, 2016. [In Chinese]
7. 中華民國兒童癌症基金會：兒童惡性淋巴瘤。http://www.ccfroc.org.tw/child/child_affection_read.php?a_id=13。引用2015/12/23。Childhood Cancer Foundation. Lymphoma. Available at: http://www.ccfroc.org.tw/child/child_affection_read.php?a_id=13. Accessed December 23, 2015. [In Chinese]
8. Food and Drug Administration. Early communication about an ongoing safety review of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070725.htm. Accessed August 6, 2017.
9. Andersen, RM(1995).Revisiting the behavioral model and access to medical care: does it matter?.J Health Soc Behav,36,1-10.
10. Bernatsky, S,Ramsey-Goldman, R,Clarke, A(2006).Malignancy and autoimmunity.Curr Opin Rheumatol,18,129-34.
11. Beukelman, T,Haynes, K,Curtis, JR(2012).Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis Rheum,64,1263-71.
12. Coussens, LM,Werb, Z(2002).Inflammation and cancer.Nature,420,860-7.
13. Diak, P,Siegel, J,La Grenade, L,Choi, L,Lemery, S,McMahon, A(2010).Tumor necrosis factor α blockers and malignancy in children: forty‐eight cases reported to the Food and Drug Administration.Arthritis Rheum,62,2517-24.
14. Katz, JN,Barrett, J,Liang, MH,Kaplan, H,Roberts, WN,Baron, JA(1998).Utilization of rheumatology physician services by the elderly.Am J Med,105,312-8.
15. Kok, VC,Horng, JT,Huang, JL(2014).Populationbased cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis.BMC Cancer,14,634.
16. Lai, NS,Tsai, TY,Li, CY,Koo, M,Yu, CL,Lu, MC(2014).Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: a national population-based study.Arthritis Care Res,66,371-8.
17. Liang, JA,Sun, LM,Yeh, JJ(2012).Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study.Rheumatol Int,32,773-8.
18. Liang, Y,Yang, Z,Qin, B,Zhong, R(2014).Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis.Ann Rheum Dis,73,1151-6.
19. Mantovan, A,Allavena, P,Sica, A,Balkwill, F(2008).Cancerrelated inflammation.Nature,454,436-44.
20. Ruperto, N,Martini, A(2014).Juvenile idiopathic arthritis and malignancy.Rheumatology,53,968-74.
21. See, LC,Kuo, CF,Chou, IJ,Chiou, MJ,Yu, KH(2013).Sexand age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study.Semin Arthritis Rheum,43,381-6.
22. Trinchieri, G(2012).Cancer and inflammation: an old intuition with rapidly evolving new concepts.Annu Rev Immunol,30,677-706.
23. Yabroff, KR,Lamont, EB,Mariotto, A(2008).Cost of care for elderly cancer patients in the United States.J Natl Cancer Inst,100,630-41.
24. Yu, KH,Kuo, CF,Huang, LH,Huang, WK,See, LC(2016).Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan.Medicine,95,e3540.
25. Zhang, JQ,Wan, YN,Peng, WJ(2013).The risk of cancer development in systemic sclerosis: a meta-analysis.Cancer Epidemiol,37,523-7.
26. 白其卉(2010)。打一場公平的拳賽—淺談選樣時的可比性。台灣腦中風學會會訊，17，10-1。
27. 兒童過敏氣喘免疫及風濕病醫學會(2015)。兒童特發性關節炎─2015年治療建議。台北=Taipei:兒童過敏氣喘免疫及風濕病醫學會=Taiwan Academy of Pediatric Allergy Asthma and Immunology。
28. 周光宇(2013)。桃園=Taoyuan，國立中央大學系統生物與生物資訊研究所=Master & PhD Program in Systems Biology and Bioinformatics, National Central University。
29. 蔡永富、周貝倫、張麟生(2007)。修格連氏症候群。基層醫學，22，264-9。